Purpose: Cisplatin plus 5-fluorouracil has been globally accepted as a standard regimen for the treatment for advanced gastric cancer. However, cisplatin has several disadvantages, including renal toxicity and the need for admission. S-1 plus cisplatin has become a standard treatment for advanced gastric cancer in East Asia. This phase III study was designed to evaluate the potential benefits of adding docetaxel to S-1 without a platinum compound in patients with advanced gastric cancer. Methods: Patients were randomly assigned to receive docetaxel plus S-1 or S-1 alone. The docetaxel plus S-1 group received docetaxel on day 1 and oral S-1 on days 1-14 of a 21-day cycle. The S-1 alone group received oral S-1 on days 1-28 of a 42-day cycle. The primary end point was overall survival. Results: Of the 639 patients enrolled, 635 were eligible for analysis. The median overall survival was 12.5 months in the docetaxel plus S-1 group and 10.8 months in the S-1 alone group (p = 0.032). The median progression-free survival was 5.3 months in the docetaxel plus S-1 group and 4.2 months in the S-1 alone group (p = 0.001). As for adverse events, neutropenia was more frequent in the docetaxel plus S-1 group, but remained manageable. Conclusion: As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone. (ClinicalTrials.gov number: NCT00287768).
Bibliographical noteFunding Information:
JACCRO and KCSG employees contributed to the study design and data collection and interpretation. This study was supported by an unconditioned grant from Sanofi K.K. Japan. Sanofi K.K. Japan had no role in the study design, data collection, analysis, or interpretation, or in writing
Acknowledgments This study was supported by the Japan Clinical Cancer Research Organization (JACCRO) and Korean Cancer Study Group (KCSG). We thank all of our patients and their families, as well as all of the site investigators. We are grateful to Dr. Y. Shimada of National Cancer Center Hospital and to Dr. T. Sasaki of Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital for their kind advice as members of the Independent Data Monitoring Committee. The authors are indebted to Prof. J. Patrick Barron of the Department of International Medical Communications of Tokyo Medical University for his review of this manuscript.
Conflict of interest Yeul Hong Kim has received the grants from Sanofi, Jeil Pharmaceutical, Pfizer, Astra Zeneca, Merck Serono, Novartis, and Roche, as well as honoraria for lectures from Sanofi, Jeil Pharmaceutical, Merck Serono, and Roche and a travel grant from Sanofi. Masashi Fujii has received consulting fees and honoraria for lectures from Taiho Pharmaceutical. Hyun Cheol Chung has received a grant from Sanofi. Akinori Takagane has received travel and hotel grants from JACCRO. Kazuhiro Yoshida has received grants from Chugai Pharmaceutical, Kyowa Hakko Kirin, Pfizer, Sanofi, Taiho Pharmaceutical, and Yakult Honsha, as well as honoraria for lectures from Chugai Pharmaceutical, Kyowa Hakko Kirin, Novartis, Pfizer, Sanofi, Taiho Pharmaceutical, and Yakult Honsha. He also has consultant or advisory relationships with Taiho Pharmaceutical and Roche. All other authors have declared no conflicts of interest.
All Science Journal Classification (ASJC) codes
- Cancer Research